EL7.AI
StocksMedium•17 November 2026•
3 min read

Wegovy pills log 3.6 million prescriptions in Q3, lift Novo sales

Key Facts

1Wegovy pill sales in the United States were DKK 4,178 million in the third quarter of 2026, with about 3.6 million prescriptions during the quarter and more than 8 million since launch.
2Novo raised its 2026 growth outlook for adjusted sales and adjusted operating profit to a range of -2% to +2% for each, compared with the previous range of -6% to 0%.
3Novo’s obesity drug sales rose 22% at constant exchange rates to DKK 26,146 million in the third quarter of 2026.
4Adjusted sales were DKK 79,195 million in the third quarter of 2026, up 4% at constant exchange rates.

Wegovy pills recorded about 3.6 million prescriptions in the United States in the third quarter of 2026, generating sales of DKK 4,178 million, according to a filing by Novo Nordisk with the U.S. Securities and Exchange Commission. The company said prescriptions have exceeded 8 million since the pills were launched. It added that this made it the strongest launch by prescription volume of any GLP-1 drug in the United States. The figures put the pills among the growth drivers of the company’s portfolio, as Novo attributed its higher full-year outlook to improved sales of GLP-1 products. These commercial indicators came alongside an increase in obesity drug sales in the same quarter.

The company’s adjusted sales in the third quarter were DKK 79,195 million, up 4% at constant exchange rates. Novo attributed the growth to higher sales volumes of GLP-1 products in both operating units, partly offset by lower realized prices. Obesity drug sales rose 22% at constant exchange rates to DKK 26,146 million, driven by higher sales volumes across the GLP-1 portfolio and geographic regions. In International Operations, obesity drug sales rose 24%, with continued demand for Wegovy partly offsetting lower realized prices. Wegovy pill sales in those markets were DKK 1,216 million during the quarter.

Chief Executive Mike Doustdar said the company had delivered “a stronger-than-expected third quarter” and was raising its full-year outlook for adjusted sales and adjusted operating profit. In its November 4 update, Novo said it now expected both adjusted sales and adjusted operating profit to grow between -2% and +2% at constant exchange rates in 2026. The previous range for both was between -6% and 0%, according to its August 4 outlook. The company attributed the improved outlook to higher expectations for sales of GLP-1 products. It said the adjusted operating profit outlook also takes into account targeted investments in research and development and commercial activities, including preparations for the launch of CagriSema in the United States.

Novo said reported sales for the first nine months of 2026 benefited from the reversal of a DKK 26.8 billion rebate provision in the first quarter. In the corresponding period of 2025, sales benefited from the reversal of a DKK 2.6 billion provision in the second quarter. The company said the reversals had no cash impact. These adjustments provide context for reading reported sales alongside the constant-exchange-rate growth rates cited by the company. Novo set February 3, 2027, as the date for announcing its 2026 financial results.

Open on chart